Table 1. Clinical characteristics of recipients and operational factors classified by graft histological features.
| Variables | Non-steatosis group | MiS group | MaS group | Mixed steatosis group | P valuea |
|---|---|---|---|---|---|
| Number (%) | 122 (49.8) | 55 (22.4) | 48 (19.6) | 20 (8.1) | NA |
| Steatosis degree | 0 | 14.9±9.4 | 12.7±7.7 | 14.8±12.5 | 0.28 |
| Recipient variables | |||||
| Age (years) | 50.3±10.7 | 54.8±8.3* | 48.7±10.9 | 47.9±9.1 | <0.05 |
| Gender (M/F) | 98/24 | 45/10 | 44/4 | 17/3 | 0.35 |
| BMI (kg/m2) | 23.8±3.6 | 23.3±2.7 | 23.4±3.6 | 23.1±3.0 | 0.67 |
| Blood type (A/B/O/AB) | 44/37/32/9 | 19/12/18/6 | 16/9/22/1 | 7/5/5/3 | 0.28 |
| Indication for liver transplantation, n (%) | |||||
| HBV/HCV related cirrhosis | 29 (23.8) | 12 (21.8) | 17 (35.4) | 8 (40.0) | 0.22 |
| Alcohol related cirrhosis | 5 (4.1) | 0 | 1 (2.1) | 2 (10.0) | |
| Alcohol + virus related cirrhosis | 3 (2.5) | 1 (1.8) | 0 | 0 | |
| PBC/PSC | 3 (2.5) | 1 (1.8) | 0 | 0 | |
| Liver cancer | 78 (63.9) | 38 (69.1) | 27 (56.3) | 9 (45.0) | |
| Others | 4 (3.3) | 3 (5.5) | 3 (6.3) | 1 (5.0) | |
| Type 2 diabetes, n (%) | 108 (88.5) | 49 (89.1) | 45 (93.8) | 18 (90.0) | 0.79 |
| Pre-operative AFP (ng/mL) | 23.9 (3.3–335.6) | 13.6 (2.3–137.8) | 7.9 (2.1–89.9) | 7.3 (3.1–237.5) | 0.35 |
| HBV infectors, n (%) | 87 (71.3) | 39 (70.9) | 35 (72.9) | 16 (80.0) | 0.87 |
| Post-LT peak TB level (U/L) | 189±19.2 | 181±30.9 | 248±32.9 | 206±36.2 | 0.49 |
| Post-LT peak ALT level (U/L) | 995±76.8 | 1,166±113.7 | 1,860±299.1* | 1,567±299.4 | <0.05 |
| Post-LT peak AST level (mg/dL) | 2,178±197.5* | 3,099±407.9 | 4,839±736.3 | 4,825±1,425.7 | <0.05 |
| MELD score | 22.3±5.1 | 24.0±3.2 | 22.6±3.3 | 21.2±4.2 | 0.36 |
| EAD occurrence, n (%) | 13 (10.7)* | 10 (18.2) | 10 (20.8) | 8 (40.0) | <0.05 |
| PNF occurrence, n (%) | 0 | 1 (1.8) | 3 (6.3)* | 0 | <0.05 |
| Patients’ survival time after LT (days) | 324±154 | 312±173 | 274±177 | 324±154 | 0.72 |
| Grafts’ survival time after LT (days) | 324±154 | 301±176 | 266±185 | 324±154 | 0.46 |
| Operational variables | |||||
| Blood transfusion | |||||
| pRBC (U) | 2 (0–6.5) | 2 (0–4.5) | 4 (2–8)* | 2 (0.5–6.1) | <0.05 |
| FFP (mL) | 830 (710–1,140) | 800 (620–990) | 865 (600–1,230) | 825 (757–990) | 0.24 |
| PCC (U) | 2 (0–5) | 3 (0–5) | 4.4 (0.5–7.8) | 3 (0–8) | 0.76 |
| Blood loss (mL) | 1,000 (800–1,800) | 1,000 (800–1,500) | 1,500 (1,000–2,500)* | 1,000 (800–1,200) | <0.05 |
| Surgical duration (mins) | 301±65.5 | 299±78.1 | 313±79.4 | 274±47.8 | 0.27 |
| Steatosis degree (%) | 0 | 14.9±9.4 | 12.7±7.7 | 14.8±12.5 | 0.28 |
Data was presented in mean ± SD for data in normal distribution and median (IQR) for data in abnormal distribution. One-way ANOVA test was assayed for normal distributed data; Mann-Whitney U test was assayed for abnormal distributed data; and chi-square test was assayed for patient distribution. * represents the significant difference compared to other groups. a, comparison was performed in groups using grafts with MiS, MaS, and mixed steatosis. AFP, alpha fatoprotein; ALT, alanine aminotransferase; AST, aspertate aminotransferase; BMI, body mass index; EAD, early allograft dysfunction; F, female; FFP, fresh frozen plasma; HBV, hepatitis b virus; HCV, hepatitis C virus; ICU, intensive care unit; LT, liver transplantation; M, male; MELD, Model for End-Stage Liver Disease; NA, not available; TB, total bilirubin; PBC, primary biliary cholangitis; PNF, primary non-function; pRBC, packed red blood cells; PCC, prothrombin complex concentrate; PSC, primary sclerosing cholangitis.